SEARCH

SEARCH BY CITATION

References

  • 1
    Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 5967.
  • 2
    Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 (Suppl. 1): 37.
  • 3
    Orr WC. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 2005; 17: 11320.
  • 4
    Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 150714.
  • 5
    Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 13017.
  • 6
    Luo JY, Niu CY, Wang XQ, Zhu YL, Gong J. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J Gastroenterol 2003; 9: 25836.
  • 7
    Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 261620.
    Direct Link:
  • 8
    Bytzer P, Blum A, De Herdt D, Dubois D. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004; 20: 1818.
  • 9
    Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 2004; 49: 9316.
  • 10
    National Institute of Clinical Excellence (NICE). Clinical guideline on management of dyspepsia in adults in primary care. August 2004.